News Quantified

KRYS – krystal biotech, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Assessing Krystal Biotech (KRYS) Valuation After Recent Share Price Weakness [Yahoo! Finance]

MRNA, SRPT, and KRYS Phase 3 Data Will Shape XBI's 2026 Performance [Yahoo! Finance]

Krystal Biotech (KRYS) is now covered by Wolfe Research. They set a "peer perform" rating on the stock.

Krystal Biotech (KRYS) was downgraded by Weiss Ratings from "buy (b-)" to "hold (c+)".

Updated YJUVEK Label and KB803 Progress Could Be A Game Changer For Krystal Biotech (KRYS) [Yahoo! Finance]

4.1%

BEAT

1.5%

BEAT

-20.2%

BEAT

-13.8%

MISS

Form ARS Krystal Biotech, Inc. For: Dec 31

Form DEFA14A Krystal Biotech, Inc.

Form DEF 14A Krystal Biotech, Inc. For: Apr 03

Form SCHEDULE 13G/A Krystal Biotech, Inc. Filed by: VANGUARD GROUP INC

Form 3 Krystal Biotech, Inc. For: Mar 01 Filed by: Goux Laurent Louis Jean

Top News Gainers

6/24 Form 8-K Krystal Biotech, Inc. For: Jun 24 41.3%

3/18 Form 4 Krystal Biotech, Inc. For: Mar 16 Filed by: Krishnan Suma 12.1%

7/1 Krystal Biotech, Inc. Added to the Russell 2000 Index 9.5%

3/10 Krystal Biotech Inc (NASDAQ: KRYS) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $100.00 price target on the stock. 9.1%

6/27 Form 8-K Krystal Biotech, Inc. For: Jun 24 8.1%

11/4 Krystal Biotech Inc (NASDAQ: KRYS) had its "buy" rating re-affirmed by analysts at William Blair. 7.5%

4/13 Form DEF 14A Krystal Biotech, Inc. For: May 29 7.3%

11/21 Form 4 Krystal Biotech, Inc. For: Nov 19 Filed by: Riley Antony A 6.3%

11/27 Krystal Biotech Inc (NASDAQ: KRYS) was upgraded by analysts at BidaskClub from a "buy" rating to a "strong-buy" rating. 5.9%

8/27 Krystal Biotech Announces Attendance at Citi’s 14th Annual Biotech Conference 5.8%

Top News Decliners

9/27 Krystal Biotech Announces Granting of its First Foreign Patent and Reinforces its IP Portfolio with a New U.S. Patent -13.6%

6/14 Krystal Submits Investigational New Drug (IND) Application for KB105, Topical Gene Therapy Candidate for Transglutaminase-1 Deficient Autosomal Recessive Congenital Ichthyosis -11.2%

9/24 Krystal Biotech Inc (NASDAQ: KRYS) is now covered by analysts at Goldman Sachs Group Inc. They set a "neutral" rating on the stock. -11.0%

12/18 Form 4 Krystal Biotech, Inc. For: Dec 16 Filed by: Krishnan Suma -10.8%

2/25 Krystal Biotech Announces Change in Financial Leadership -8.0%

8/2 Krystal Biotech Inc (NASDAQ: KRYS) was downgraded by analysts at ValuEngine from a "strong-buy" rating to a "buy" rating. -7.0%

7/23 Krystal Biotech Inc (NASDAQ: KRYS) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $55.00 price target on the stock. -6.9%

2/18 Form SC 13G Krystal Biotech, Inc. Filed by: ORBIMED ADVISORS LLC -5.3%

6/25 Krystal Biotech Inc (NASDAQ: KRYS) had its price target raised by analysts at Guggenheim from $48.00 to $73.00. They now have a "buy" rating on the stock. -5.2%

9/30 Krystal Biotech Inc (NASDAQ: KRYS) was given a new $81.00 price target on by analysts at Guggenheim. They now have a "buy" rating on the stock. -4.5%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day